Literature DB >> 30570424

Approaches to monitoring intussusception following rotavirus vaccination.

Jacqueline E Tate1, Umesh D Parashar1.   

Abstract

INTRODUCTION: In 1998, the first licensed rotavirus vaccine was associated with intussusception, an unexpected adverse event, following reports of this condition to an adverse event reporting system. This rotavirus vaccine was withdrawn from the market and newer rotavirus vaccines have been extensively evaluated for an association with intussusception. AREAS COVERED: We review the different study designs that have been used both pre- and post-licensure to evaluate the association of rotavirus vaccines with intussusception and discuss the pros and cons of each design. Each of these study designs has their own strengths and weaknesses and the choice of the design often depends on the objective and the timing of the study and the resources available. For post-licensure monitoring of rotavirus vaccines, the self-controlled case-series design has become the most commonly used design to monitor this association. EXPERT OPINION: Use of this common study design has enabled comparison of findings across diverse settings. As new rotavirus vaccines enter the market, use of the self-controlled case-series design will enable examination of this association in a timely manner.

Entities:  

Keywords:  Rotavirus vaccine; adverse event following immunization; intussusception; rotavirus

Mesh:

Substances:

Year:  2018        PMID: 30570424      PMCID: PMC8845486          DOI: 10.1080/14740338.2019.1561857

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  37 in total

1.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Authors:  Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Lack of an apparent association between intussusception and wild or vaccine rotavirus infection.

Authors:  M B Rennels; U D Parashar; R C Holman; C T Le; H G Chang; R I Glass
Journal:  Pediatr Infect Dis J       Date:  1998-10       Impact factor: 2.129

3.  Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit Study.

Authors:  Chee-Fu Yung; Siew Pang Chan; Sally Soh; Adriana Tan; Koh Cheng Thoon
Journal:  J Pediatr       Date:  2015-04-14       Impact factor: 4.406

4.  Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants.

Authors:  J Joensuu; E Koskenniemi; T Vesikari
Journal:  Pediatr Infect Dis J       Date:  1998-04       Impact factor: 2.129

5.  Intussusception Rates Before and After the Introduction of Rotavirus Vaccine.

Authors:  Jacqueline E Tate; Catherine Yen; Claudia A Steiner; Margaret M Cortese; Umesh D Parashar
Journal:  Pediatrics       Date:  2016-08-24       Impact factor: 7.124

6.  Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger.

Authors:  Sheila Isanaka; Ousmane Guindo; Celine Langendorf; Amadou Matar Seck; Brian D Plikaytis; Nathan Sayinzoga-Makombe; Monica M McNeal; Nicole Meyer; Eric Adehossi; Ali Djibo; Bruno Jochum; Rebecca F Grais
Journal:  N Engl J Med       Date:  2017-03-23       Impact factor: 91.245

7.  Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach.

Authors:  Sylvie Escolano; Catherine Hill; Pascale Tubert-Bitter
Journal:  Vaccine       Date:  2015-01-14       Impact factor: 3.641

8.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Authors:  K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

Review 9.  Rotavirus vaccines: an overview.

Authors:  K Midthun; A Z Kapikian
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

10.  Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.

Authors:  Nita Bhandari; Temsunaro Rongsen-Chandola; Ashish Bavdekar; Jacob John; Kalpana Antony; Sunita Taneja; Nidhi Goyal; Anand Kawade; Gagandeep Kang; Sudeep Singh Rathore; Sanjay Juvekar; Jayaprakash Muliyil; Alok Arya; Hanif Shaikh; Vinod Abraham; Sudhanshu Vrati; Michael Proschan; Robert Kohberger; Georges Thiry; Roger Glass; Harry B Greenberg; George Curlin; Krishna Mohan; G V J A Harshavardhan; Sai Prasad; T S Rao; John Boslego; Maharaj Kishan Bhan
Journal:  Lancet       Date:  2014-03-12       Impact factor: 79.321

View more
  1 in total

1.  The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.

Authors:  N Henschke; H Bergman; D Hungerford; N A Cunliffe; R F Grais; G Kang; U D Parashar; S A Wang; K M Neuzil
Journal:  Vaccine       Date:  2022-02-17       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.